Unfractionated heparin is one of the oldest and most widely used anticoagulant drugs in medicine, and it remains a frontline therapy in hospitals worldwide more than a century after its discovery. It works by supercharging a natural protein in your blood called antithrombin, which then shuts down several clotting enzymes at once. Unlike newer blood thinners that you swallow as a pill, unfractionated heparin is given by injection or intravenous drip, acts within minutes, and can be reversed quickly if bleeding becomes a concern. That combination of speed, potency, and reversibility is why it still holds a central place in cardiac surgery, dialysis, and the treatment of dangerous blood clots, even as alternatives have multiplied around it.
How It Stops Clotting
Your blood contains a built-in brake on clotting called antithrombin. Under normal conditions, antithrombin slowly neutralizes clotting enzymes, keeping clot formation in check. Heparin accelerates that process dramatically. Structural studies show that heparin binding can speed up antithrombin’s inhibition of clotting enzymes by up to 10,000-fold.1PubMed Central. Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation It does this through two routes. For some enzymes, heparin physically bridges antithrombin and the target enzyme together, holding them in contact long enough for antithrombin to latch on. For others, heparin changes antithrombin’s shape so it becomes a far more aggressive hunter of clotting factors on its own. The result is a broad shutdown of the clotting cascade rather than a surgical strike on a single enzyme, which is part of what makes unfractionated heparin so powerful and so tricky to dose precisely.
Where Heparin Comes From
Almost all pharmaceutical heparin is extracted from pig intestines. Each American pig yields roughly 300 milligrams of purified heparin, and the drug is produced globally in quantities measured in tons.2PubMed Central. Lessons learned from the contamination of heparin China, as the world’s largest pork producer, dominates the raw material supply. That concentration carries real risk. In 2008, a viral disease swept through Chinese pig herds, creating a sudden shortage of raw material. The gap was filled with adulterated heparin contaminated with a cheap sulfated polysaccharide mimic. That contamination caused roughly 80 deaths and hundreds of serious allergic reactions before regulators traced the problem.3Wiley Online Library. Imminent risk of a global shortage of heparin caused by the African Swine Fever afflicting the Chinese pig herd
The threat resurfaced in 2018 when African Swine Fever began devastating Chinese pig herds again, raising alarms about another potential global shortage.4Wiley Online Library. Imminent risk of a global shortage of heparin caused by the African Swine Fever afflicting the Chinese pig herd It is a genuinely fragile supply chain: a single animal species from a single dominant producing country supporting a drug that hospitals cannot function without. Bovine lung heparin exists as an alternative raw material, and some countries use it, but porcine intestinal heparin remains the standard in the United States and Europe. The two differ slightly in their chemical makeup; porcine heparin has a slightly different binding site structure for antithrombin compared with the bovine version.5PubMed Central. Lessons learned from the contamination of heparin
How It Moves Through Your Body
One of unfractionated heparin’s quirks is that its pharmacokinetics are not straightforward. After injection, the drug is cleared from the bloodstream by two different routes. At lower doses, most of it is grabbed by cells in the liver, spleen, and blood vessel walls, a fast and saturable process. At higher doses, that cellular uptake gets overwhelmed and kidney excretion takes over.6PubMed. Pharmacokinetics of heparin and low molecular weight heparin The practical effect is that the relationship between dose and blood levels is not a clean, predictable line. Double the dose and you may more than double the anticoagulant effect, because you have saturated the fast clearance pathway and a larger fraction of the drug persists in circulation. This is why heparin requires continuous monitoring, and why getting the dose right in a given patient can be fiddly.
Monitoring the Dose
Because heparin’s effect varies so much from patient to patient, clinicians cannot just set a drip rate and walk away. The traditional monitoring test is the activated partial thromboplastin time, or aPTT. It measures how long a blood sample takes to clot in a test tube. When heparin is working, clotting time stretches. The target range is typically 1.5 to 2.5 times a patient’s baseline value, though this varies by institution.
The problem with the aPTT is that many things besides heparin affect it. Inflammation, liver disease, high levels of certain clotting factors, and even the specific reagent a lab uses can all shift results. An alternative test, the anti-factor Xa assay, measures heparin’s effect more directly by quantifying how much the drug inhibits one specific clotting enzyme. In head-to-head comparisons, patients monitored with anti-Xa reached their target range faster and needed fewer dose adjustments. One study found a mean time to therapeutic anticoagulation of about 28 hours with anti-Xa versus 48 hours with aPTT.7PubMed. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion Patients in the anti-Xa group also spent a greater share of their time within the therapeutic window, about two thirds of measurements versus closer to four in ten for the aPTT group.8PubMed. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion
Despite that improvement in precision, a systematic review pooling data from over 6,600 patients found no significant difference in bleeding, blood clots, or mortality between the two monitoring approaches.9PubMed. Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: A systematic review and meta-analysis The two tests disagreed with each other about whether a patient was therapeutic nearly half the time in one study, which underscores how imprecise heparin dosing really is.10PubMed Central. Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms Anti-Xa testing is gaining ground at many hospitals, but both methods remain in widespread use.
When Heparin Stops Working
Sometimes a patient receives a normal dose of heparin and the aPTT barely budges, a situation called heparin resistance. Several things can cause this. The most common culprit is low levels of antithrombin itself; since heparin works by boosting antithrombin, there is a floor effect when the protein is depleted, as happens in severe illness, liver disease, or prolonged heparin use. Other causes include high levels of acute-phase proteins in the blood that bind heparin before it can reach antithrombin, elevated factor VIII activity, and increased heparin clearance from an enlarged spleen.11PubMed Central. To be or not to be a case of heparin resistance There are also mundane explanations: occasionally the heparin line is kinked or disconnected, producing what looks like pharmacological resistance but is really a plumbing failure. Clinicians typically respond by escalating the dose, switching to anti-Xa monitoring, or in some cases supplementing antithrombin directly.
Heparin-Induced Thrombocytopenia
The most feared complication of heparin therapy is a paradoxical immune reaction called heparin-induced thrombocytopenia, or HIT. Instead of simply thinning the blood, heparin occasionally triggers the immune system to produce antibodies against complexes of heparin and a platelet protein known as platelet factor 4 (PF4). Those antibodies then activate platelets through their surface receptors, causing them to release clot-promoting particles.12Blood. Heparin-induced thrombocytopenia The result is a dangerous combination: the platelet count drops (because platelets are being consumed) while new blood clots form in arteries and veins. HIT can cause strokes, limb-threatening clots, and death if it is not recognized quickly.
Fortunately, true HIT is uncommon. In one intensive care study of 528 patients on heparin, only two cases were confirmed by the gold-standard laboratory test, an incidence of about 0.4%.13PubMed. The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients The challenge is that plenty of critically ill patients develop low platelet counts for other reasons, so doctors need a way to sort signal from noise. The most widely used screening tool is the 4Ts score, which weighs the timing and severity of the platelet drop, the presence of new blood clots, and whether another cause is more likely. In a prospective evaluation, the 4Ts score had a perfect negative predictive value: every patient scored as low probability turned out not to have HIT on confirmatory testing.14PubMed. Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia A low 4Ts score, in other words, is very good at ruling HIT out, which spares most patients from unnecessary changes in therapy.
When HIT is confirmed or strongly suspected, all heparin must be stopped immediately and replaced with a non-heparin anticoagulant. The traditional alternatives have been direct thrombin inhibitors given intravenously, though recent reviews have begun evaluating direct oral anticoagulants as a more convenient option for some patients.15PubMed. Systematic Literature Review of DOACs as Treatment for Confirmed or Suspected Heparin-Induced Thrombocytopenia (HIT)
Reversing the Effect
One of unfractionated heparin’s key advantages over many newer anticoagulants is that it can be turned off quickly. The antidote is protamine, a small, positively charged protein originally derived from fish sperm. Protamine binds heparin through simple electrostatic attraction, positive charges on protamine locking onto negative charges on heparin in a one-to-one ratio. The resulting complex is inactive and forms within seconds, appearing as a visible white suspension in a test tube.16British Journal of Anaesthesia. Protamine and its reversal: a narrative review At the same time, protamine strips heparin away from the heparin-antithrombin complex, restoring antithrombin to its normal, slower-acting state.
Protamine is indispensable in cardiac surgery, where patients receive large doses of heparin during cardiopulmonary bypass and then need their clotting restored before the chest is closed. But protamine itself is not without issues. At higher doses, it has its own anticoagulant properties, interfering with clotting factors and platelet function.17PubMed Central. Protamine and Heparin Interactions: A Narrative Review It can also trigger allergic or anaphylactoid reactions in up to one in ten patients, and it commonly causes a drop in blood pressure. One proposed mechanism for the hypotension involves calcium being consumed as the coagulation cascade reactivates after protamine reverses heparin, leaving too little circulating calcium to maintain normal vascular tone.18Cellular and Molecular Biology. A new mechanism of the protamine-dependent hypotension after cardiopulmonary bypass and the role of calcium Anesthesiologists typically give protamine slowly and in calculated doses to minimize these reactions.
Unfractionated Heparin Versus Low Molecular Weight Heparins
Low molecular weight heparins like enoxaparin and dalteparin are produced by chemically or enzymatically chopping standard unfractionated heparin into smaller fragments. Because of their smaller size, these fragments behave more predictably in the body: they have better absorption after a subcutaneous injection, a longer half-life, and a more consistent dose-response relationship. For most patients, that means they can be given as a fixed-dose shot once or twice a day without routine blood monitoring.19PubMed. Unfractionated versus low-molecular-weight heparin in the treatment of venous thromboembolism They also tend to cause less bleeding for a comparable level of clot prevention.
So why does unfractionated heparin persist? Partly because of the situations where its supposed disadvantages become advantages. Its short, unpredictable half-life is actually useful in unstable patients who might need surgery at short notice or who are bleeding. Its dependence on monitoring is an advantage when you need precise, hour-by-hour control of anticoagulation. And its complete reversibility with protamine has no true equivalent for the low molecular weight versions, which protamine only partially neutralizes. Patients on heparin drips in an ICU, people undergoing cardiac surgery or interventional procedures, and those with rapidly changing kidney function are all populations where unfractionated heparin’s profile makes it the better tool.
Kidney Disease and Pregnancy
Two patient groups where unfractionated heparin has a particularly important role are people with severe kidney disease and pregnant women. Low molecular weight heparins are cleared largely through the kidneys, so in patients with end-stage renal disease they accumulate unpredictably and carry a higher bleeding risk. Unfractionated heparin, which is cleared mainly by cellular uptake rather than by the kidneys, avoids this problem. Guidelines give a strong recommendation for using unfractionated heparin over low molecular weight heparins to treat blood clots in patients with severe renal failure, and it remains the standard anticoagulant for the dialysis circuit itself.20PubMed. The safety of heparins in end-stage renal disease21PubMed. Subcutaneous unfractionated heparin for treatment of venous thromboembolism in end-stage renal disease
In pregnancy, the critical fact is that neither unfractionated heparin nor low molecular weight heparins cross the placenta, so they pose no direct risk to the developing fetus from bleeding or birth defects.22Journal of Thrombosis and Haemostasis. Management of venous thromboembolism during pregnancy This makes heparins the anticoagulant class of choice for pregnant patients who need blood-thinning therapy. Warfarin crosses the placenta and can cause serious fetal harm, and most direct oral anticoagulants lack sufficient safety data in pregnancy. Low molecular weight heparins are generally preferred for routine use during pregnancy because they are easier to give at home, but unfractionated heparin is sometimes chosen near delivery because its short duration of action and reversibility allow better control of bleeding risk during labor or cesarean section.23Journal of Thrombosis and Thrombolysis. A descriptive evaluation of unfractionated heparin use during pregnancy
Beyond Blood Thinning
Heparin has biological activities that have nothing to do with clotting. It damps down inflammation, interferes with microbial attachment to cells, and helps thin and mobilize airway mucus.24PubMed Central. Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease These properties have generated decades of research into using heparin or heparin-derived molecules for conditions like acute respiratory distress syndrome, cystic fibrosis, and smoke inhalation injury. Some of this work uses modified forms of heparin that have had their anticoagulant activity stripped out, keeping the anti-inflammatory and mucoactive effects without the bleeding risk. None of these applications have become mainstream clinical practice yet, but the breadth of heparin’s pharmacology is a reminder that it is not just a one-trick molecule.
IV Compatibility in the Hospital
Heparin drips often run alongside other intravenous medications in critically ill patients, and not all of those drugs play nicely together. A recent compatibility study testing 28 commonly used intensive-care medications found that heparin was among the drugs most frequently involved in physical incompatibilities when mixed at Y-site connectors. Combinations involving heparin, along with drugs like furosemide, ketamine, and certain antibiotics, produced visible precipitation or haziness that disqualified them from safe co-administration through the same line.25BMJ Journals. Y-site compatibility of co-administered continuous infusion solutions in intensive care units: preparatory study on physicochemical compatibility of 28 relevant medicinal products This is a practical headache for nurses and pharmacists: heparin’s strongly negative charge makes it prone to forming insoluble complexes with positively charged drugs. The workaround is usually to run incompatible drugs through a separate IV line or to flush the line between infusions, but in patients with limited venous access this can be a genuine logistical challenge.
The Future of the Supply Chain
The dependence on porcine intestines for a drug this essential has pushed researchers toward synthetic alternatives. A chemoenzymatic process developed in recent years can produce bioengineered heparin without any animal tissue. The resulting product has been shown to be compositionally and biologically similar to standard porcine-derived heparin, including matching its molecular weight range and functional properties.26PubMed Central. Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin The process is also scalable and can be converted to produce low molecular weight heparin equivalents. If it clears regulatory hurdles, bioengineered heparin would eliminate the animal-disease vulnerability and the contamination risk that have shadowed the porcine supply chain. It would also address religious and cultural objections to porcine-derived medicines. The timeline to widespread clinical use remains uncertain, but the technical feasibility of producing animal-free heparin at meaningful scale appears to have been demonstrated.
A Discovery That Almost Did Not Happen
Heparin’s discovery is one of medicine’s more convoluted origin stories. In 1916, a second-year medical student named Jay McLean, working in William Henry Howell’s physiology lab at Johns Hopkins, extracted fat-soluble compounds from dog liver that had unexpected anticoagulant effects in the test tube and caused excessive bleeding in lab animals.27Nature Reviews Cardiology. Discovery and purification of heparin Howell continued the work after McLean left, and by 1918, working with another student, he had isolated a different anticoagulant from liver tissue. Howell named it “heparin,” from the Greek word for liver. Over the next decade, he refined the extraction process and eventually identified the active substance as a water-soluble polysaccharide in 1926, a compound chemically distinct from what McLean had originally found.28Nature Reviews Cardiology. Discovery and purification of heparin Credit for the discovery has been debated ever since; McLean’s initial observation opened the door, but Howell developed it into a characterized substance.29Physiology. Discovery of Heparin: Contributions of William Henry Howell and Jay McLean It would take another two decades of purification work by other researchers, most of it in Sweden and Canada, before heparin was safe and pure enough for routine use in patients. That a chance observation by a medical student in 1916 produced a drug still central to hospital medicine more than a hundred years later is a striking reminder of how circuitous medical progress can be.